GlassScriptPhysician profile
Nicole Warner
NPI 1710244397
$592.56
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $104 · 2024: $13.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $182.36 | 2019 | |
| Lilly USA, LLC | $79.62 | 2019-2020 | |
| Pfizer INC. | $78.59 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $68.52 | 2019 | |
| Almirall LLC | $34.78 | 2019-2020 | |
| Abbvie INC. | $25.08 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.77 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.82 | 2020 | |
| Sun Pharmaceutical Industries INC. | $15.12 | 2019 | |
| Dusa Pharmaceuticals, INC. | $14.75 | 2019 | |
| Meditrina | $13.95 | 2024 | |
| Dermira, INC. | $13.85 | 2019 | |
| Leo Pharma INC. | $11.24 | 2019 | |
| Ucb, INC. | $11.11 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Warner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.